October 5, 2020 07:10 AM EDTUpdated 08:51 AM

Ransomware attack hit clinical trials software player ERT — two weeks later, they’re coming back online

Arsalan Arif

Founder

One of the largest biomedical ransomware attacks in US history was revealed last week, when IT systems at 250 locations in a major American hospital …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ransomware attack hit clinical trials software player ERT — two weeks later, they’re coming back online

Arsalan Arif

Founder

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?

Ran­somware at­tack hit clin­i­cal tri­als soft­ware play­er ERT — two weeks lat­er, they’re com­ing back on­line

Arsalan Arif

Founder

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Ransomware attack hit clinical trials software player ERT — two weeks later, they’re coming back online

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?